Predicine company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series B - II | Alive

Total Raised


Last Raised

$12.69M | 2 yrs ago

About Predicine

Predicine is focused on the development of liquid biopsy diagnostic techniques. The company has developed an integrated "one-stop-shop" biomarker service platform to conduct big data analysis to enable precision medicine in personalized cancer care and global drug development. Predicine operates in Hayward, California, and Shanghai, China.

Predicine Headquarter Location

3555 Arden Road

Hayward, California, 94545,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Predicine

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Predicine is included in 7 Expert Collections, including Cancer.



3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'


Medical Devices

7,913 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

15,795 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Health Monitoring & Diagnostics

2,470 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Digital Health

12,795 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Predicine Patents

Predicine has filed 3 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Genetics
  • Molecular biology
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Genetics, Biotechnology, DNA, DNA sequencing


Application Date


Grant Date



Related Topics

Molecular biology, Genetics, Biotechnology, DNA, DNA sequencing



Latest Predicine News

Predicine Liquid Biopsy Outperforms in ctDNA Assay Study

May 13, 2022

Predicine , a global molecular insights company, announced the results of a new research study that showed its PredicineATLAS liquid biopsy next-generation sequencing (NGS) assay outperforming four other leading assays for key metrics. The manuscript, “Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panels,” was released online ahead of publication in  PLOS ONE . The side-by-side study was led by a team of Bristol Myers Squibb (BMS) scientists who evaluated five leading large gene panel circulating tumor DNA ( ctDNA ) NGS assays. Identical blinded reference panels that simulated clinical cell-free DNA samples were supplied to and tested by each vendor. Resulting data was summarized and delivered to BMS scientists who performed detailed unbiased analyses of each assay’s performance. The study found that in key metrics, including detection sensitivity, specificity, accuracy, and reproducibility, the 600-gene PredicineATLAS (referred to as “Assay B” in the study) outperformed all other tested assays. For example, at the low DNA input level (10ng), PredicineATLAS delivered the highest sensitivity among all assays. In addition, PredicineATLAS demonstrated 100% specificity (i.e., no false positives). In terms of accuracy, PredicineATLAS most closely mirrored the expected mutation fraction, especially at low level (0.125%), delivering the highest accuracy among the five tested assays. Of note, the study also reported that PredicineATLAS not only exhibited the highest median coverage depth at the low DNA input level (10ng), but also the highest background noise filtration rate, highlighting the robustness of the Predicine NGS workflow and bioinformatics pipeline. In addition, the Predicine assay was also the only liquid biopsy platform examined in the study capable of detecting gene deletion or copy number reductions (CNR). The paper highlighted that: “Assay B eliminated over 95% of background noise through its bioinformatics pipeline without using a germline DNA sample as a control. This is impressive, considering Assay B also achieved the highest sensitivity among the five assays.” “Liquid biopsy assays with large gene panels have not been systematically assessed through direct comparison studies,” says Massimo Cristofanilli, MD, director of Breast Medical Oncology and Associate Director for Precision Oncology at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, who was not involved in this study. “This study shows that, while all technologies show comparable sensitivity, some differences emerge. I believe that the results of this study are highly informative and provide a desired framework to evaluate and select suitable liquid biopsy assay platforms for clinical implementation including patient testing, clinical trial, and companion diagnostics (CDx) development.”  Predicine is developing a portfolio of liquid biopsy and tissue NGS assays for early cancer detection, treatment selection, therapy monitoring, minimal residual disease (MRD) monitoring and disease progression. “We are very pleased with the outcome of this important side-by-side direct comparison,” says Shidong Jia, MD, PhD, Predicine’s founder and global CEO. “Following our mission to empower the global healthcare ecosystem through innovation, it is gratifying to see the outperformance of Predicine liquid biopsy assay in this carefully conducted study. This brings us one step closer to manifesting our vision of bringing the best hospital to every community and bringing the best doctor to every home.” Harmonized assays are available for research, clinical investigation, and CDx development across Predicine’s global lab network in U.S., China, and soon in Europe as well. Current use of the assays includes patient testing under CLIA guidelines, patient enrollment testing for global therapeutic trials, and global CDx development. Share:

Predicine Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Predicine Rank

You May Also Like


AnchorDx is a precision medicine company engaged in the clinical research & development of targeted DNA methylation high-throughput sequencing solutions for the early diagnosis of cancer.


Diagu is an internationally operating company that is part of the Microsoft for Start-ups program, working on a solution that will help diagnose patients better, more accurately and faster through an in-depth analysis of their laboratory test results using artificial intelligence.

Lunit Logo

Lunit is a medical AI software company devoted to providing AI solutions for cancer diagnostics and therapeutics. With its deep learning technology, Lunit makes data-driven medicine the new standard of care. Lunit AI solutions help discover cancer and predict cancer treatment response by finding the right diagnosis at the right costs and the right treatment for the right patients.

nference Logo

nference offers a platform that enables a diverse set of applications ranging from R&D to commercial strategy and operations in the life sciences ecosystem. nference makes biomedical knowledge computable and builds its AI platform to serve as the connective fabric for various silos of information that exist across health care enterprises.

NuProbe Logo

NuProbe brings together cutting-edge developments in molecular engineering with scientific expertise and management to take on of the world's greatest challenges - non-invasive early detection of rare genetic variants in patients. NuProbe will take a multi-platform approach to apply these breakthrough technology capability in precision medicine to cancer diagnostics, NIPT, and infectious disease screening, building on scientific findings.

Molecular You

Molecular You analyzes a range of biomarkers to show health risks and what the user can do about it. Its preventive health assessment analyze not only genetics, but also metabolites, proteins, nutrients, and toxins to give the user the full picture. Then, it designs a personal diet and fitness plan to help the user stay healthy.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.